Clover Health releases transcript of 2Q26 supplemental Q&A on earnings call
CLOV•Supplemental shareholder Q&A highlights
Clover Health posted a 2Q26 supplemental shareholder Q&A transcript featuring remarks from CEO Andrew Toy.
- Cohort maturation under Clover Assistant was cited as a key driver, with year-3 members generating about $155 PMPM more insurance gross profit than year-1.
- The year-3 Clover Assistant-managed cohort showed an MCR about 18% better than non-assisted members, framed as compounding economics over time.
- CMS rated Clover’s PPO and HMO plans at 4.5 Stars for the 2027 payment year, and management said it is operating on that basis.
- Counterpart Health was positioned to prioritize lives under management and demonstrate impact before material financial contribution, with “real-time value-based payment” models under consideration.
